Who are Ramucirumab+ paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): REGORAFENIB, Sutent, Anlotinib(blank), CKD-828, Ramucirumab DP (IMC-1121B), TAS-102, Regorafenib , Fruquintinib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramucirumab-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ramucirumab+ paclitaxel — Competitive Intelligence Brief

Ramucirumab+ paclitaxel (Ramucirumab+ paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiogenesis inhibitor, Microtubule inhibitor. Area: Oncology.

phase 3 Angiogenesis inhibitor, Microtubule inhibitor VEGFR2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ramucirumab+ paclitaxel (Ramucirumab+ paclitaxel) — AstraZeneca. Ramucirumab is a monoclonal antibody that targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, while paclitaxel is a microtubule inhibitor that blocks cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramucirumab+ paclitaxel TARGET	Ramucirumab+ paclitaxel	AstraZeneca	phase 3	Angiogenesis inhibitor, Microtubule inhibitor	VEGFR2
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01
Anlotinib(blank)	Anlotinib(blank)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Multi-targeted tyrosine kinase inhibitor	VEGFR2, FGFR1, PDGFR-β, c-Kit, Ret
CKD-828	CKD-828	Chong Kun Dang Pharmaceutical	phase 3	Dual VEGFR2/FGFR1 tyrosine kinase inhibitor	VEGFR2, FGFR1
Ramucirumab DP (IMC-1121B)	Ramucirumab DP (IMC-1121B)	Eli Lilly and Company	phase 3	VEGF inhibitor	VEGFR2
TAS-102, Regorafenib , Fruquintinib	TAS-102, Regorafenib , Fruquintinib	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Nucleoside analog, Multi-kinase inhibitor, VEGFR2 inhibitor	Thymidylate synthase, VEGFR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiogenesis inhibitor, Microtubule inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramucirumab+ paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/ramucirumab-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab